Article Text
PDF
Abstract
Mesalazine is a common treatment for inflammatory bowel disease and can be rarely associated with myopericarditis. We report a case of a 19-year-old man recently diagnosed with ulcerative colitis and started on mesalazine, who presented with chest pain 2 weeks after beginning this therapy. Blood tests demonstrated elevated troponin I. ECG and echocardiographic changes were consistent with myopericarditis. When mesalazine was reintroduced 2 weeks after discharge, he suffered from myopericarditis again. On cessation of the drug, the cardiac symptoms resolved in combination with anti-inflammatory therapy. The onset of symptoms after mesalazine, and improvement of chest pain and cardiac biomarkers after discontinuing the drug, suggest that our patient suffered from a rare drug-hypersensitivity reaction to mesalazine.
- cardiovascular medicine
- pericardial disease
- cardiovascular system
- contraindications and precautions
Statistics from Altmetric.com
Footnotes
Contributors TD was responsible for data collection, literature review, writing of the manuscript and submitted the manuscript for publication. AS, RMS and AC provided critical revision of the article and final approval of the published version.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent Obtained.
Provenance and peer review Not commissioned; externally peer reviewed.